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Abstract
Cyclin dependent kinase-5 (cdk5)/p35 is a neuronal kinase that regulates key axonal and synaptic functions but the
mechanisms by which it is transported to these locations are unknown. Lemur tyrosine kinase-2 (LMTK2) is a binding
partner for p35 and here we show that LMTK2 also interacts with kinesin-1 light chains (KLC1/2). Binding to KLC1/2
involves a C-terminal tryptophan/aspartate (WD) motif in LMTK2 and the tetratricopeptide repeat (TPR) domains in
KLC1/2, and this interaction facilitates axonal transport of LMTK2. Thus, siRNA loss of KLC1 or mutation of the WD motif
disrupts axonal transport of LMTK2. We also show that LMTK2 facilitates the formation of a complex containing KLC1
and p35 and that siRNA loss of LMTK2 disrupts axonal transport of both p35 and cdk5. Finally, we show that LMTK2
levels are reduced in Alzheimer’s disease brains. Damage to axonal transport and altered cdk5/p35 are pathogenic
features of Alzheimer’s disease. Thus, LMTK2 binds to KLC1 to direct axonal transport of p35 and its loss may contribute
to Alzheimer’s disease.
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Introduction
Dynamic changes to protein phosphorylation underpin
many aspects of neuronal function. p35 is a binding
partner and activator subunit of the neuronal serine-
threonine kinase cdk5 [7, 23, 43, 47]. Together with
cdk5, p35 regulates a variety of fundamental physio-
logical processes within neurons including synaptic
vesicle trafficking, dopaminergic and glutaminergic sig-
nalling, and axonal functions involving axonal outgrowth
and the regulation of transport of cargoes through axons
(axonal transport) [1, 7, 20, 36, 43]. In addition, damage
to p35 leading to altered cdk5/p35 activity is believed to
contribute to the pathogenesis of Alzheimer’s disease
[7, 41, 43]. Despite the major roles that p35 plays
within axons and synapses, the mechanisms by which
it is transported into and through axons to these
locations are unknown. Understanding these mecha-
nisms is essential for properly comprehending p35
and cdk5 function in neurons and also its dysfunction
in Alzheimer’s disease.
In addition to binding cdk5, p35 also binds to LMTK2
(also known as brain-enriched kinase, apoptosis-associated
tyrosine kinase-2, kinase/phosphatase/inhibitor-2, cdk5/p35
regulated kinase, lemur tail kinase-2 and KIAA1079)
[18, 28]. LMTK2 is a member of the lemur family of
kinases which are a structurally unique group of ki-
nases that are anchored in the membrane by a
membrane-spanning region located at their extreme
N-termini and which contain an N-terminally located
kinase domain with a long C-terminal “tail” [3, 17,
18, 46, 53, 56]. As such, they have been named after
lemurs, the long-tailed Madagascan primates. Topography
studies have confirmed earlier predictions that LMTK2 is
orientated so that its C-terminal tail projects into the
cytosol [37]. Although originally predicted to be a
dual-specificity serine-threonine/tyrosine kinase, several
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studies have since shown that LMTK2 only targets serine
and threonine residues [17, 27, 28, 53, 54]. In neurons,
LMTK2 along with p35 is enriched in cell bodies and the
Golgi but is also present in axons and axon termini [18].
Kinesin-1 is a major microtubule-associated molecular
motor that mediates transport of a wide variety of car-
goes within neurons [13]. In axons, microtubule orienta-
tion is nearly uniform with the plus ends pointing
toward the synapse and the minus ends facing the cell
body. Since kinesin-1 unidirectionally moves toward
microtubule plus ends, in axons it mostly drives antero-
grade transport toward the synapse. A proportion of
functional kinesin-1 comprises a hetero-tetramer of two
kinesin-1 motor proteins and two kinesin-1 light chains;
KLC1 and KLC2 are the best characterized light chains
[13, 31]. Kinesin-1 contains ATPase activity and uses the
chemical energy of ATP to drive conformational changes
that generate motile force; in contrast, the KLCs are
mainly involved in binding of cargoes.
The importance of kinesin-1 driven axonal transport
suggests that any disruption to this process may be detri-
mental to neurons. Indeed, damage to axonal transport is
strongly implicated in Alzheimer’s disease [2, 5, 9, 30, 55].
Here we show that LMTK2 interacts with KLC1/2 and
that this interaction facilitates its anterograde transport
through axons. We also show that LMTK2 mediates the
formation of a complex containing KLC1 and p35 and
that siRNA loss of LMTK2 disrupts axonal transport of
both p35 and cdk5. Finally, we show that LMTK2 levels
are reduced in affected regions in post mortem Alzhei-
mer’s disease brains. Loss of LMTK2 may therefore con-
tribute to Alzheimer’s disease by effects on axonal
transport of p35 and cdk5.
Materials and methods
Plasmids and siRNAs
pCI-neo control empty vector was from Promega.
Myc-tagged mouse LMTK2, FLAG-tagged mouse KLC1
and KLC2, hemagglutinin (HA)-tagged human cdk5 and
HA-, EGFP- and DsRed-tagged p35 plasmids were as de-
scribed previously [12, 27, 51, 58]. C-terminal EGFP-
tagged LMTK2 was generated by PCR amplification of
LMTK2 [27] so as to remove the stop codon and cloning
into pEGFP-N1 (Clontech) as a XhoI-HindIII fragment.
Primers were 5′-AAACTCGAGATGCCGGGGCCGCC
GGCG-3′ and 5′-AAAAAGCTTCTAGTCCTTGTCTC
CGTCTTCAC-3′. N-terminally myc-tagged mouse kinesin-
1A was generated by PCR from kinesin-1A IMAGE clone
(BC058396; GeneService) and cloning into pCI-neo as a
NheI-NheI fragment. Primers were 5′-AAAGCTAGC
GAACAAAAACTCATCTCAGAAGAGGATCTGATGGC
GGAGACTAACAACGAA -3′ and 5′-AAAGCTAGCTTA
GCTGGCTGCTGTCTCTT-3′. N-terminal EGFP-tagged
cdk5 was generated by subcloning HA-cdk5 into pEGFP-C1
(Clontech) as a BamHI-BamHI fragment. Mutant proteins
were generated using a QuikChange II XL site-directed mu-
tagenesis kit (Agilent Technologies) according to the manu-
facturer’s instructions with the following primer pairs:
LMTK2(WE477/478AA) 5′-AGCTTTGAGTATGTGG
CGGCGGCTGCCAAGCACGAC-3′ and 5′-GTCGTGC
TTGGCAGCCGCCGCCACATACTCAAAGC-3′.
LMTK2(WD1388/1389AA) 5′-GGCGGAGGCTTTG
AAGCGGCCGATGACTTCTCCCCG-3′ and 5′-CGGG
GAGAAGTCATCGGCCGCTTCAAAGCCTCCGCC-3′.
KLC1(N302L) 5′-GGCAGCGACTCTGAACCTCCTA
GCAGTACTGTACGG-3′ and 5′-CCGTACAGTACTG
CTAGGAGGTTCAGAGTCGCTGCC-3′.
KLC2(N287L) 5′-GGCTGCGACCCTCAACCTTCTG
GCTGTTCTCTACGGC-3′ and 5′-GCCGTAGAGAAC
AGCCAGAAGGTTGAGGGTCGCAGCC-3′.
All constructs were verified by sequencing.
LMTK2, KLC1 and control siRNAs (Accell range)
were from Dharmacon Horizon Discovery. LMTK2
siRNA was a pool of four constructs: 5′-GCCUGAGCU
UUGAGUACGU-3′, 5′-CCCUUGGGUUUGUUGAAU
U-3′, 5′-GUGUGCAGUUUAAUGGUAC-3′ and 5′-GA
AAUAGACUUUAAGGAAU-3′.
KLC1 siRNA was 5′-GGGUCGUCUUUUGGAGAGU-3′.
Antibodies
The following primary antibodies were used in this study:
rabbit anti-cdk5 (C-8, Santa Cruz; 1/500 immunoblot
(IB)), mouse anti-FLAG (M2, Sigma; 1/250 immunopre-
cipitation (IP), 1/2000 IB), rabbit anti-GFP (Abcam; 1/
250 IP; 1/5000 IB), mouse anti-GFP (B-2, Santa Cruz; 1/
1000 IB), rabbit anti-HA (Sigma; 1/2000 IB; 1/500 im-
munofluorescence (IF)), mouse anti-kinesin-1 (H2, Milli-
pore; 1/3000 IB), rabbit anti-KLC1 (H-75, Santa Cruz; 1/
2000 IB), goat anti-KLC1 (L-15, Santa Cruz; 1/100 PLA),
rabbit anti-LMTK2 (ab24782 Abcam; 1/500 IB), rabbit
anti-LMTK2 (EPR7836(2); Abcam; 1/500 IB), rabbit
anti-LMTK2 (described previously [18] 1/100 PLA),
mouse anti-myc (9B11, Cell Signaling; 1/250 IP; 1/2000
IB; 1/2000 IF), mouse anti neuron specific enolase (NSE;
Dako; 1/50,000 IB), rabbit anti-p35 (C-19, Santa Cruz; 1/
100 PLA), rabbit-anti p35/25 (C64B10; Cell Signaling; 1/
2000 IB), mouse anti-tubulin (DM1A, Sigma; 1/20,000
IB), mouse anti-β-tubulin isotype III (SDL.3D10; Sigma;
1/500 IF).
Cell culture and transfection
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium with 4.5 g/l glucose (GE Healthcare) supple-
mented with 10% (v/v) fetal bovine serum and 2mM
L-glutamine. Cells were transfected using TurboFect
(Thermo Scientific) or with polyethylenimine MAX
(Polysciences) according to the manufacturer’s instruc-
tions. Cells were analysed 24 h post-transfection.
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Rat cortical neurons were obtained from embryonic
day 17 embryos, plated on poly-L-lysine coated 18mm
diameter glass coverslips (Marienfield GmbH & Co.KG)
or on 35mm diameter glass bottom μ-dishes (Ibidi
GmbH) and cultured in Neurobasal medium containing
B27 supplement (Invitrogen), 2 mM L-glutamine, 100
IU/ml penicillin and 100 μg/ml streptomycin. Neurons
were transfected using Lipofectamine 2000 (Invitrogen)
(2 μl/μg DNA in Opti-MEM) according to the manufac-
turer’s instructions and analysed 24 h post transfection
on DIV6 or 7. siRNAs were applied at DIV2 for 96 h.
SDS-PAGE and immunoblotting
Cells were harvested for SDS-PAGE and immunoblot-
ting by scraping into SDS-PAGE sample buffer contain-
ing 2% (w/v) SDS, 100 mM dithiothreitol, 10% (w/v)
glycerol, 0.1% (w/v) bromophenol blue and protease in-
hibitors (Complete Roche) in 50 mM Tris-HCl pH 6.8
and heating to 96 °C for 5 min. Other samples were pre-
pared by addition of SDS-PAGE sample buffer and heat-
ing to 100 °C for 5 min. Samples from cell cultures were
separated on 8 or 12% gels using Mini-PROTEAN 3 gel
electrophoresis systems (Bio-Rad) with a discontinuous
buffer system. Human post-mortem brain homogenates
were separated on Novex 4–12% Tris-Glycine Plus Midi
Protein gels (Invitrogen) using the XCell4 Sureloc
Midi-Cell system (Invitrogen). Separated proteins were
transferred to BioTrace NT nitrocellulose membrane
(0.2 μm pore size; Pall Corporation) using a Mini
Trans-Blot electrophoretic transfer cell (Bio-Rad) for 16
h or a Midi Trans-Blot electrophoretic transfer cell
(Bio-Rad) for 2 h. Membranes were blocked with
Tris-HCl buffered saline (TBS) containing 5% (w/v) milk
powder and 0.1% (w/v) Tween-20 for 1 h or with Odys-
sey TBS blocking buffer (Li-Cor Biosciences) for 1 h.
Membranes were probed with primary antibodies in
blocking buffers supplemented with 0.1% (w/v)
Tween-20 (TBS/Tween-20), washed in TBS/Tween-20
and incubated with horseradish peroxidase (HRP)-conju-
gated secondary antibodies in wash buffer, and developed
using an enhanced chemiluminescence development re-
agent (GE Healthcare) and exposure on Hyperfilm ECL.
Alternatively, blots were incubated with IRDye-conjugated
secondary antibodies in wash buffer and proteins visua-
lised using an Odyssey CLx near infrared imaging system
(Li-Cor Biosciences).
Signals on Hyperfilm ECL developed immunoblots
were quantified using ImageJ (version 1.50b; developed
by Wayne Rasband, National Institute of Health,
Bethesda, USA) after scanning with an Epson Precision
V700 Photo scanner as described by us in earlier studies
[34]; only signals within the linear optical density range
were used for analyses. Signals obtained with Odyssey
CLx imaging system were quantified by Image Studio
Lite (version 5.2.5; Li-Cor Biosciences). LMTK2 signals
obtained from human brain samples were normalised to
NSE signals from the same membrane.
Immunoprecipitation assays
Immunoprecipitation assays were performed essentially
as described [34]. Briefly, cells were washed with phos-
phate buffered saline (PBS) and harvested by scraping
into ice-cold immunoprecipitation lysis buffer (50 mM
Tris-citrate pH 7.4; 150 mM NaCl; 1% (v/v) Triton
X-100; 5 mM EGTA; 5 mM EDTA and protease inhibi-
tors (Complete, Roche)) for 1 h. Following centrifugation
at 15,000 x g for 30 min at 4 °C, samples were incubated
with primary antibody for 16 h at 4 °C. Antibodies were
captured using Protein G-sepharose beads (50% (v/v) in
PBS supplemented with 0.1% (v/v) Triton X-100) for 2 h
at 4 °C, washed in capture buffer and bound proteins
eluted and prepared for SDS-PAGE by incubation in
50 μl SDS-PAGE sample buffer and heating at 96 °C for
5 min.
Preparation of human brain samples for SDS-PAGE and
immunoblotting
Post-mortem human frontal cortex and cerebellum sam-
ples from control and pathologically confirmed cases of
Alzheimer’s disease were obtained from the Medical Re-
search Council Neurodegenerative Diseases Brain Bank,
King’s College London. All tissue collection and process-
ing were carried out under the regulations and licensing
of the Human Tissue Authority, and in accordance with
the Human Tissue Act, 2004. Post mortem studies from
some control, clinically non-demented individuals re-
vealed early Braak stage pathologies. Frozen human
brain tissues were prepared as 20% homogenates in
ice-cold radioimmunoprecipitation assay (RIPA) buffer
(50 mM Tris-HCl pH 7.4; 150 mM NaCl; 1 mM EDTA;
1% (v/v) Triton X-100; 0.5% (w/v) sodium deoxycholate;
0.1% (w/v) SDS) with protease and phosphatase inhibitor
cocktails (Roche) using a Bio-Gen PRO200 rotor-stator
homogeniser (Pro Scientific) for 20 s. Following hom-
ogenisation, each sample was sonicated three times for
3 s before being centrifuged at 13,000 x g for 20 min at
4 °C. Supernatants were collected and protein concentra-
tions determined using a bicinchoninic acid protein
concentration assay kit (Pierce) according to the manu-
facturer’s instructions. Protein concentrations were ad-
justed to the same concentration in each sample by
adding RIPA and SDS-PAGE sample buffers. Samples
were stored at − 80 °C and heated to 96 °C for 10 min
prior to SDS-PAGE.
Immunofluorescence microscopy
Cells were fixed in 4% (w/v) paraformaldehyde in PBS
for 15 min, washed three times in PBS, quenched with
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50mM NH4Cl in PBS for 15 min and permeabilised with
0.2% (v/v) Triton X-100 in PBS for 3 min. Cells were
blocked with 3% (w/v) bovine serum albumin in PBS for
30 min and incubated with primary antibodies in block-
ing solution for 1 h. Following washing with PBS, the
primary antibodies were detected using donkey anti-
mouse Igs coupled with Cy5 (Jackson Immuno Re-
search), goat anti-mouse and anti-rabbit Igs coupled
with AlexaFluor 488, or 546 (Invitrogen) in blocking so-
lution. After washing in PBS the samples were mounted
in fluorescence mounting medium (Dako) or Mowiol-
DABCO containing 10% (w/v) Mowiol 4–88 (Calbiochem),
25% (w/v) glycerol and 1% (w/v) DABCO (1,4-diazobicyclo
[2.2.2] octane) in 100mM Tris–HCl pH 8.5.
Images were captured using a Leica DM5000 B micro-
scope equipped with 40x/0.75NA HCX-PL-FLUOTAR
objective, DFC360 FX camera and appropriate filter sets
(Leica). Axonal LMTK2, p35 and cdk5 levels were each
acquired using the same microscope settings and quanti-
fied using ImageJ. To do so, background corrected
non-saturated fluorescent axonal and cell body density
signals were acquired and each axonal signal then nor-
malised to its corresponding cell body signal.
Proximity ligation assays
Proximity ligation assays (PLAs) were performed with
rabbit anti-LMTK2 and goat anti-KLC1, and with rabbit
anti-p35 and goat anti-KLC1 antibodies using Duolink
PLA probes and orange detection reagent (Sigma) ac-
cording the manufacturer’s protocol. Briefly, cells were
fixed and permeabilised as described above for immuno-
fluorescence staining, blocked with PLA blocking buffer
for 30 min at 37 °C and incubated with primary anti-
bodies for 1 h. Following washing, samples were incu-
bated with PLA probes for 1 h at 37 °C and after further
washing, probes were ligated for 30 min at 37 °C and
amplified for 100 min at 37 °C. Following PLAs, cells
were incubated with tubulin primary antibody in PBS at
4 °C for 16 h, washed with PBS and incubated with fluor-
escent conjugated secondary antibody for 1 h in PBS.
Following further washing, samples were mounted as de-
scribed above. Control reactions to demonstrate the spe-
cificity of the assays involved omission of primary
antibodies. Signals were quantified using ImageJ particle
analysis function as described [42].
Time-lapse microscopy
Axonal transport of EGFP- and DsRed-tagged LMTK2,
p35 and cdk5 in living neurons was monitored using a
Nikon Eclipse Ti-E microscope equipped with Intens-
light C-HGFI light source (Nikon), EGFP and DsRed fil-
ter sets (Chroma Technology), CFI Apo Lambda S 60x/
1.40 objective (Nikon) and an Andor Neo scientific com-
plementary metal-oxide-semiconductor camera (Andor
Technology). Movements were recorded using NIS-Ele-
ments AR software (Nikon). Particles were imaged 24–
36 h post-transfection in Ibidi μ-dishes or by mounting
coverslips in a Ludin imaging chamber (Life Imaging
Services) filled with external solution (145 mM NaCl, 2
mM KCl, 5mM NaHCO3, 1 mM MgCl2, 2.5 mM
CaCl2, 10mM glucose in 10mM HEPES pH 7.0).
Temperature was maintained at 37 °C during imaging
using a microscope incubation chamber (Solent Scien-
tific). Movements were recorded at 1 s time-lapse intervals
and 100ms exposure times. Kymographs were created
using the Straighten and Kymograph plugins of ImageJ. In
line with our previous studies, we chose cells expressing
low levels of transfected proteins (as judged by the fluor-
escent protein signal) for analyses so as to avoid any pos-
sible artefacts produced by high levels of expression [1,
50].
Statistical analyses
Statistical analysis was performed using Excel (Microsoft
Corporation), Prism software (version 7.02; GraphPad
Software Inc.) and SPSS (version 24.0.0.1; IBM). Statis-
tical significance was determined by t-test or analysis of
variance (ANOVA) followed by post-hoc test as described
in figure legends. Data are plotted as mean ± s.e.m. All ex-
periments were repeated at least three times.
Results
LMTK2 binds to KLCs via a C-terminal WD motif
We tested whether LMTK2 might bind to KLC1 and
KLC2 in immunoprecipitation assays. To do so, we
transfected HEK293 cells with either empty pCIneo con-
trol vector, myc-tagged LMTK2 (myc-LMTK2), FLAG-
tagged KLC1 (FLAG-KLC1), FLAG-KLC2, myc-LMTK2
+ FLAG-KLC1 or myc-LMTK2 + FLAG-KLC2 and mon-
itored the LMTK2-KLC1/KLC2 interaction on immuno-
blots following immunoprecipitation of either LMTK2,
KLC1 or KLC2 via their epitope tags. LMTK2 bound to
both KLC1 and KLC2 in these assays and the interaction
was only detected in LMTK2 +KLC1/KLC2 co-transfected
cells which demonstrates the specificity of the assays
(Fig. 1a).
The mechanisms by which cargoes attach to kinesin-1
motors are not fully understood but one route involves
interactions between the TPR domains in KLC1/2 and
cargo located tryptophan-aspartate/tryptophan-glutamate
(WD/WE) motifs [10, 33, 40]. Mutation to leucine of con-
served asparagines within the KLC TPRs (KLC1(N302)
and KLC2(N287)) has been shown to disrupt WD/WE
cargo binding [40, 59]. We therefore studied binding of
LMTK2 to mutant KLC1(N302L) and KLC2(N287L)
using immunoprecipitation assays similar to those de-
scribed above. Mutant KLC1(N302 L) did not bind and
KLC2(N287 L) displayed reduced binding to LMTK2 in
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these assays (Fig. 1b, c). Differences in binding of WD/WE
containing proteins to KLC1 and KLC2 have been de-
scribed previously [10, 49].
LMTK2 contains two conserved WE/WD motifs that
might potentially interact with the KLC TPR domains
(WE477/478 and WD1388/1389). We therefore mutated
LMTK2(WE477/478) and LMTK2(WD1388/1389) sep-
arately to double alanine, and again monitored binding
of the mutants to KLC1 and KLC2 in immunoprecipita-
tion assays. Mutant LMTK2(WE477/478AA) bound to
Fig. 1 LMTK2 binds to both KLC1 and KLC2 via a C-terminal WD motif (a.a. 1388/1389). a LMTK2 binds to KLC1 and KLC2. HEK293 cells were
transfected with either control empty vector (Ctrl), myc-LMTK2, FLAG-KLC1, FLAG-KLC2, myc-LMTK2 + FLAG-KLC1 or myc-LMTK2 + FLAG-KLC2.
LMTK2, KLC1 and KLC2 were each immunoprecipitated via their epitope tags and bound KLC1/KLC2 or LMTK2 detected by immunoblotting. No
signals for co-immunoprecipitated proteins were obtained in control cells transfected with only one plasmid which demonstrates the specificity
of the assays. Both inputs and immunoprecipitates (IP) are shown. b and c Mutation of KLC1(N302) or KLC2(N287) to leucine within their TPR
domains disrupts binding to LMTK2. HEK293 cells were transfected with control vector, myc-LMTK2 + FLAG-KLC1, myc-LMTK2 + FLAG-
KLC1(N302L), myc-LMTK2 + FLAG-KLC2 or myc-LMTK2 + FLAG-KLC2(N287L). myc-LMTK2 was immunoprecipitated via the myc-tag and bound
KLC1 (b) or KLC2 (c) detected on immunoblots. Mutant KLC1(N302L) did not bind to LMTK2 and KLC2(N287L) displayed reduced binding to
LMTK2. Both inputs and immunoprecipitates are shown. Graph in (c) shows relative levels of KLC2 bound to LMTK2 in the immunoprecipitations
following quantification of signals on immunoblots. Data were analysed by t-test. N = 5; error bars are s.e.m., *p < 0.05. Both inputs and
immunoprecipitations (IP) are shown. d and e Mutation of LMTK2 WD (1388/1399) but not WE (477/478) to AA disrupts binding to KLC1 and KLC2.
HEK293 cells were transfected with control vector, myc-LMTK2 + FLAG-KLC1/KLC2, myc-LMTK2(WE477/478) + FLAG-KLC1/KLC2 or myc-LMTK2(WD1388/
1389) + KLC1/KLC2. LMTK2 was immunoprecipitated via its epitope tag and bound KLC1 (d) or KLC2 (e) detected by immunoblotting. Mutation of
LMTK2 WD/AA (1388/1389) abolished binding of KLC1 and markedly inhibited binding of KLC2. Both inputs and immunoprecipitates are shown. Bar
chart in (e) shows relative levels of KLC2 bound to LMTK2 in the immunoprecipitations following quantification of signals on immunoblots. Data were
analysed by one-way ANOVA and Tukey’s post hoc test. N = 3; error bars are s.e.m., *p < 0.05.
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both KLC1 and KLC2 in a manner indistinguishable
from wild-type LMTK2 (Fig. 1d, e). However, mutant
LMTK2(WD1388/1389AA) did not bind to KLC1 and
displayed reduced binding to KLC2 (Fig. 1d, e). These
findings complement the above studies showing that
mutation of the KLC1 TPR domain had a more potent
effect on binding to LMTK2 than mutation of the KLC2
TPR domain (Fig. 1b, c). We therefore focussed on the
LMTK2-KLC1 interaction. KLC1 has been shown to be
involved in transporting a large number of cargoes in
axons [11, 44, 52].
We next used immunoprecipitation assays to deter-
mine whether LMTK2 is complexed with the kinesin-1
motor. To do so, we immunoprecipitated EGFP-tagged
wild-type LMTK2 or LMTK2(WD1388/1389AA) from
FLAG-KLC1 +myc-kinesin-1 co-transfected HEK293
cells. Both KLC1 and kinesin-1 bound to LMTK2 but
not LMTK2(WD1388/1389AA) in these assays (Fig. 2a).
Finally, we used PLAs to test whether endogenous
LMTK2 and KLC1 were associated with each other in
cultured HEK293 cells and rat cortical neurons. These
PLAs produced positive signals which in the neurons in-
cluded in cell bodies and axons (Fig. 2b, c). In both
HEK293 cells and neurons, confocal analyses revealed
that the KLC1-LMTK2 PLA signals were particularly
abundant in perinuclear regions but not within nuclei.
This is in agreement with previous studies which show
that LMTK2 is enriched in these areas including the
Golgi [18]. Thus, LMTK2 binds to both KLC1 and
KLC2 via a conserved WD motif in its C-terminal tail
domain (residues 1388/1389), this binding involves the
KLC TPR domains and the interaction of LMTK2 with
KLC1 facilitates its binding to the kinesin-1 motor
complex.
Axonal transport of LMTK2 involves its binding to KLC1
LMTK2 is present in neuronal cell bodies and axons
[18]. To determine whether LMTK2 delivery into
axons involves its binding to KLCs, we first studied
how siRNA depletion of KLC1 affected the axonal
distribution of transfected myc-LMTK2 in rat cortical
neurons. KLC1 siRNAs have been characterised previ-
ously [51] and induced an approximate 80% reduction
in protein levels without affecting expression of en-
dogenous kinesin-1, LMTK2, p35 or cdk5 (Add-
itional file 1: Figure S1a). Neuronal morphologies were
determined by co-transfection of DsRed and LMTK2 was
identified by immunostaining for its myc-tag. Com-
pared to untreated or control siRNA treated neurons,
KLC1 siRNA knockdown cells displayed a noticeable
reduction in axonal LMTK2 labelling. To quantify
this phenotype, we normalised axonal LMTK2 fluor-
escent signals to cell body signals in each neuron.
These analyses revealed a significant reduction in
axonal LMTK2 in the KLC1 siRNA knockdown cells
(Fig. 3a).
To complement these KLC1 siRNA knockdown studies,
we also monitored axonal localisation of transfected
wild-type myc-LMTK2 and mutant myc-LMTK2(WD1388/
1389AA) that does not bind to KLC1 in the cortical neu-
rons. Compared to wild-type LMTK2, LMTK2(WD1388/
1389AA) displayed reduced axonal labelling and we again
quantified this phenotype by normalising axonal LMTK2
fluorescent signals to cell body signals in each neuron.
These analyses confirmed that LMTK2(WD1388/1389AA)
levels were significantly reduced in axons (Fig. 3c).
We next monitored how siRNA loss of KLC1 and mu-
tation of LMTK2(WD1388/1389AA) affect axonal trans-
port of transfected EGFP-LMTK2 in living rat cortical
neurons using time-lapse microscopy. Movement of
wild-type EGFP-LMTK2 was observed in both antero-
grade and retrograde directions and the mean antero-
grade velocity was 0.58 +/− 0.42 μm/s. This velocity for
EGFP-LMTK2 movement is in line with the velocities
described for other known kinesin-1/KLC1 cargoes such
as calsyntenin-1, amyloid precursor protein (APP) and
Kidins220/ARMS [4, 50, 51]. However, siRNA loss of
KLC1 significantly reduced the numbers of anterogra-
dely moving EGFP-LMTK2 cargoes (Fig. 3b). Likewise,
compared to wild-type EGFP-LMTK2, the numbers of
EGFP-LMTK2(WD1388/1389AA) anterogradely moving
cargoes were significantly reduced (Fig. 3d). Thus, the
binding of LMTK2 to KLC1 via its WD1388/1389 motif
facilitates LMTK2 transport into and through axons.
We also calculated how siRNA loss of KLC1 and mu-
tant LMTK2(WD1388/1389) affect the proportion of
total moving LMTK2 cargoes (anterograde plus retro-
grade) and their anterograde velocities. Compared to
control siRNA, KLC1 siRNA treatment did not signifi-
cantly affect either of these parameters. However,
LMTK2(WD1388/1389) showed reduced total move-
ment (p < 0.001) compared to wild-type LMTK2 but this
did not alter its velocity. These findings are in line with
the LMTK2(WD1388/1389) mutant having a particularly
potent effect on binding to KLC1.
LMTK2 forms a complex with both KLC1 and p35
LMTK2 also binds to p35 and this interaction involves
amino acids within residues 391–632 of LMTK2 [18].
This region is located some distance from the KLC
interaction motif (WD1388/1389) we identify above
which suggests that LMTK2 may form a complex with
both p35 and KLC1. To test this possibility, we first
used immunoprecipitation assays to determine
whether mutation of LMTK2(WD1388/1389) affected
binding of p35 to LMTK2 in transfected HEK293 cells.
As predicted, immunoprecipitated LMTK2 and
LMTK2(WD1388/1389) bound equally well to p35 in
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these assays (Fig. 4a). We next tested whether LMTK2
formed a complex with KLC1 and p35 again using im-
munoprecipitation assays in transfected HEK293 cells.
Like many other non-neuronal cells lines, HEK293 cells
express endogenous cdk5 but not p35 [19]. HA-tagged
p35 was immunoprecipitated from cells co-transfected
with FLAG-KLC1 and either wild-type myc-LMTK2 or
myc-LMTK2(WD1388/1389AA) that does not bind
KLC1. p35 bound to endogenous cdk5 and both
myc-LMTK2 and myc-LMTK2(WD1388/1389AA) in
these assays. However, KLC1 was only detected in the p35
immunoprecipitates in the presence of wild-type LMTK2
(Fig. 4b). These findings demonstrate that the interaction
between p35 and KLC1 is dependent upon LMTK2. We
also used PLAs to detect interactions between endogen-
ous p35 and KLC1 in untreated rat cortical neurons, or in
neurons treated with control or LMTK2 siRNAs. LMTK2
siRNAs have been characterised previously [27] and led to
an approximate 75% reduction of LMTK2 in the neurons
(Additional file 1: Figure S1b). Control experiments in-
volving omission of p35 or KLC1 antibodies demon-
strated the specificity of these PLAs (Additional file 1:
Figure S2). Robust PLA signals were detected between
p35 and KLC1 in control cells but siRNA loss of
LMTK2 induced a significant decrease in the number
of these signals (Fig. 4c). Thus, LMTK2 mediates the
formation of a complex containing both p35 and
KLC1.
Fig. 2 LMTK2 is complexed with both KLC1 and kinesin-1 and mutation of LMTK2(WD1388/1389) to AA disrupts this binding. a HEK293 cells were
transfected with either control empty vector (Ctrl), EGFP-LMTK2 + FLAG-KLC1 +myc-kinesin-1A or EGFP-LMTK2(WD1388/1389AA) + FLAG-KLC1 +
myc-kinesin-1A. LMTK2 was immunoprecipitated via the EGFP-tag and bound KLC1 and kinesin-1 detected by immunoblotting. Both inputs and
immunoprecipitations (IP) are shown. b and c Endogenous LMTK2 and KLC1 are complexed in HEK293 cells (b) and rat cortical neurons (c).
LMTK2-KLC1 PLAs were performed using rabbit anti-LMTK2 and goat anti-KLC1 antibodies. Control experiments involving omission of both or
each primary antibody are also shown. Representative phase contrast images with PLA signals of cells are displayed; arrows indicate PLA signals
and in (c) show signals in axons. To facilitate viewing of signals in these phase contrast images, the PLAs colours were electronically changed
from red to pale blue. Scale bars = 20 μm. Graphs show PLA signals per cell in the different experiments. Data were analysed by Welch’s ANOVA
and Games-Howell post hoc test. b N = 40–46 cells, c N = 43–54 cells; error bars are s.e.m., ***p < 0.001
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Fig. 3 (See legend on next page.)
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LMTK2 is required for axonal transport of p35
The above findings suggest that LMTK2 may function
to facilitate anterograde axonal transport of p35 on
kinesin-1-KLC1 motors. We therefore monitored axonal
localization of transfected EGFP-p35 in untreated rat
cortical neurons or in neurons treated with control or
LMTK2 siRNAs. p35 was detected via its EGFP-tag and
neuronal morphology determined by co-transfection
with Ds-Red as described above. In agreement with pre-
vious studies, EGFP-p35 was present in cell bodies and
axons in control neurons [18, 20, 36]. However, siRNA
loss of LMTK2 markedly reduced EGFP-p35 axonal
levels. To quantify this reduction, we normalized axonal
fluorescent EGFP-p35 signals to those in cell bodies in a
(See figure on previous page.)
Fig. 3 siRNA loss of KLC1 and mutation of LMTK2 WD (1388/1389) disrupt axonal transport of LMTK2. a and b siRNA loss of KLC1 disrupts axonal
levels and anterograde axonal transport of LMTK2. Neurons were either untreated (UT) or treated with control or KLC1 siRNAs and then co-transfected
with myc-LMTK2 and DsRed to reveal neuronal architecture in (a) or EGFP-LMTK2 alone in (b). a Neurons were fixed and transfected LMTK2 detected by
immunostaining for its epitope tag. Representative images of neurons are displayed along with graph showing quantification of relative axonal LMTK2
levels. Scale bar = 20 μm. Data were analysed by Welch’s ANOVA and Games-Howell post hoc test; N = 28–43, error bars are s.e.m., ***p < 0.001. b
Representative kymographs showing axonal transport of EGFP-LMTK2 in living neurons; for clarity anterogradely moving EGFP-LMTK2 are
illustrated alongside, time = 180 s. Graph shows quantification of anterogradely moving LMTK2 in the different siRNA treated neurons. Data
were analysed by Welch’s ANOVA and Games-Howell post hoc test; N = 15–23, error bars are s.e.m., *p < 0.05, **p < 0.01. c and d Mutation
of LMTK2 WD (1388/1389) to AA disrupts axonal levels and anterograde axonal transport of LMTK2. c Neurons were co-transfected with
DsRed and either myc-LMTK2 or myc-LMTK2(WD1388/1389AA) and LMTK2 detected in fixed cells by immunostaining for its epitope tag.
Representative images of neurons are displayed along with graph showing quantification of relative axonal LMTK2 levels. Scale bar = 20 μm. Data were
analysed by t-test; N = 28 and 31 neurons, error bars are s.e.m., ***p < 0.001. d Representative kymographs showing axonal transport of EGFP-LMTK2
and EGFP-LMTK2(WD1388/1389AA) in living neurons; for clarity, anterogradely moving EGFP-LMTK2 are illustrated alongside, time = 180 s. Graph shows
quantification of anterogradely moving LMTK2 in the different transfected neurons. Data were analysed by t-test; N = 23–26, error bars are
s.e.m., *p < 0.05
Fig. 4 LMTK2, p35 and KLC1 form a complex. a Mutation of LMTK2(WD1388/1389AA) does not affect LMTK2 binding to p35. HEK293 cells were
transfected with either control empty vector (Ctrl), myc-LMTK2, myc-LMTK2(WD/1388/1389AA), myc-LMTK2 + p35 or myc-LMTK2(WD1388/1389AA) +
p35. LMTK2 was immunoprecipitated via the myc-tag and bound p35 detected by immunoblotting. Both inputs and immunoprecipitations (IP) are
shown. b p35 forms a complex with cdk5, LMTK2 and KLC1, and mutation of LMTK2(WD1388/1389AA) specifically disrupts KLC1 binding to the
complex. HEK293 cells were transfected with either control empty vector (Ctrl), HA-p35 +myc-LMTK2 + FLAG-KLC1 or HA-p35 +myc-LMTK2(WD1388/
1389AA) + FLAG-KLC1. p35 was immunoprecipitated via the HA-tag and bound LMTK2, KLC1 and cdk5 detected on immunoblots. Both inputs and
immunoprecipitations (IP) are shown. c LMTK2 mediates formation of a complex between KLC1 and p35 in cortical neurons. Neurons were either
untreated or treated with control or LMTK2 siRNAs and PLAs for KLC1 and p35 performed using goat anti-KLC1 and rabbit anti-p35 antibodies.
Neurons were also immunostained for tubulin to reveal architecture. KLC1-p35 signals are markedly reduced in both cell bodies and axons in LMTK2
siRNA treated neurons; arrows show PLA signals in axons. Graph shows quantification of PLA dots in axons in the different treated cells. Data were
analysed by Welch’s ANOVA and Games-Howell post hoc test; N = 15–24, error bars are s.e.m., ***p < 0.001
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manner similar to that described above for quantifying
axonal localization of LMTK2. These studies revealed a
significant reduction in axonal EGFP-p35 in LMTK2
siRNA knockdown neurons (Fig. 5a).
To complement these studies, we also monitored
whether siRNA loss of LMTK2 affected axonal transport
of transfected DsRed-p35 in living rat cortical neurons
using time-lapse microscopy. As was the case for
EGFP-LMTK2, movement of DsRed-p35 was observed
in both anterograde and retrograde directions with a
mean anterograde velocity of 0.62 +/− 0.46 μm/s. This
velocity was not significantly different to that observed
for EGFP-LMTK2 (see above) and is again similar to
those reported for other known kinesin-1/KLC1 cargoes
such as calsyntenin-1, APP and Kidins220/ARMS
[4, 50, 51]. However, compared to untreated or control
siRNA treated neurons, siRNA loss of LMTK2 induced a
significant reduction in anterograde movement of EGFP-
p35 (Fig. 5b). Together, these findings together demonstrate
that LMTK2 is required for proper axonal delivery and an-
terograde axonal transport of p35.
We also calculated how siRNA loss of LMTK2 affected
the proportion of total moving p35 cargoes (anterograde
plus retrograde) and their anterograde velocities.
Compared to control siRNA, LMTK2 siRNA treat-
ment did not significantly affect either of these pa-
rameters although there was a trend for a reduction
in total movement. It is possible that increasing sam-
ple size to generate greater statistical power will re-
veal a significant affect.
siRNA loss of LMTK2 also disrupts axonal transport of cdk5
We also enquired whether siRNA loss of LMTK2 might
disrupt axonal transport of cdk5 in a manner similar to
Fig. 5 siRNA loss of LMTK2 reduces axonal levels and anterograde axonal transport of p35. a Neurons were either untreated (UT) or treated with
control or LMTK2 siRNAs and then co-transfected with EGFP-p35 and DsRed to reveal neuronal architecture. Representative images of fixed
neurons are displayed along with graph showing quantification of relative axonal EGFP-p35 levels. Scale bar = 20 μm. Data were analysed
by Welch’s ANOVA and Games-Howell post hoc test; N = 30–34, error bars are s.e.m., *p < 0.05, **p < 0.01. b Representative kymographs
showing axonal transport of DsRed-p35 in living neurons; for clarity anterogradely moving DsRed-p35 are illustrated alongside, time = 180
s. Graph shows quantification of anterogradely moving DsRed-p35 in the different treated neurons. Data were analysed by Welch’s ANOVA and
Games-Howell post hoc test; N = 17–26, error bars are s.e.m., *p < 0.05
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that of its binding partner p35. To do so, we first moni-
tored axonal localization of transfected HA-cdk5 in un-
treated rat cortical neurons or in neurons treated with
control or LMTK2 siRNAs. Transfected cdk5 was de-
tected by immunostaining for the HA-tag and neuronal
morphology determined by co-transfection with Ds-Red
as described above. In agreement with previous studies,
HA-cdk5 was present in cell bodies and axons in control
neurons [20, 36]. However, siRNA loss of LMTK2 mark-
edly reduced axonal levels of HA-cdk5. To quantify this
reduction, we normalized axonal fluorescent HA-cdk5
signals to those in cell bodies in a manner similar to that
described above for quantifying axonal localization of
LMTK2 and p35. These studies revealed a significant re-
duction in axonal HA-cdk5 in LMTK2 siRNA knock-
down neurons (Fig. 6a).
We also enquired whether siRNA loss of LMTK2
affected axonal transport of transfected EGFP-cdk5 in
living rat cortical neurons using time-lapse microscopy.
As was the case for EGFP-LMTK2 and DsRed-p35,
movement of EGFP-cdk5 was observed in both antero-
grade and retrograde directions with a mean anterograde
velocity of 0.57 +/− 0.4 μm/s. This velocity was not sig-
nificantly different to those we observed for EGFP-
LMTK2 or DsRed-p35 (see above). However, compared
to untreated or control siRNA treated neurons, siRNA
loss of LMTK2 induced a significant reduction in an-
terograde movement of EGFP-p35 (Fig. 5b). Together,
these findings demonstrate that LMTK2 is also required
for proper axonal delivery and anterograde axonal trans-
port of cdk5.
Finally, we calculated how siRNA loss of LMTK2
affected the proportion of total moving cdk5 cargoes
(anterograde plus retrograde) and their anterograde vel-
ocities. Compared to control siRNA, LMTK2 siRNA
treatment significantly reduced both of these features
Fig. 6 siRNA loss of LMTK2 reduces axonal levels and anterograde axonal transport of cdk5. a Neurons were either untreated (UT) or treated with
control or LMTK2 siRNAs and then co-transfected with HA-cdk5 and DsRed to reveal neuronal architecture. Representative images of fixed
neurons are displayed along with graph showing quantification of relative axonal HA-cdk5 levels detected using the epitope tag. Scale
bar = 20 μm. Data were analysed by Welch’s ANOVA and Games-Howell post hoc test; N = 41–43, error bars are s.e.m., ***p < 0.001. b Representative
kymographs showing axonal transport of EGFP-cdk5 in living neurons; for clarity anterogradely moving EGFP-cdk5 are illustrated alongside, time = 180
s. Graph shows quantification of anterogradely moving EGFP-cdk5 in the different treated neurons. Data were analysed by Welch’s ANOVA and
Games-Howell post hoc test; N = 14–21, error bars are s.e.m., *p < 0.05
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(total movement reduction p ≤ 0.001; velocity reduction
p ≤ 0.001). Since LMTK2 siRNA loss had only minor ef-
fects on total movement of p35 (see above), it is possible
that these more potent effects on cdk5 reflect the need for
additional protein-protein interactions for cdk5 transport.
Thus, whilst p35 transport involves formation of a tripar-
tite KLC1-LMTK2-p35 complex, cdk5 transport requires
a quaternary complex of KLC1-LMTK2-p35-cdk5.
LMTK2 levels are reduced in cortex but not cerebellum of
Alzheimer’s disease patients
Disruption to axonal transport is a major pathogenic
event in Alzheimer’s disease [2, 5, 9, 30, 55]. Since
siRNA loss of LMTK2 perturbed axonal transport of
both p35 and cdk5, we enquired whether LMTK2 levels
might be altered in Alzheimer’s disease. To do so, we
monitored LMTK2 levels by immunoblotting in
post-mortem Alzheimer’s disease brain tissues. Details of
these human samples are shown in Table 1; there were
no significant differences in age or post-mortem delay
between the Alzheimer’s disease and control cases. We
studied LMTK2 levels in cortex and cerebellum (affected
and non-affected regions) in control, Braak stage III-IV
(mid dementia) and Braak stage VI (severe dementia)
cases. We normalised LMTK2 levels to the levels of NSE
as described by others [21, 45]. Compared to controls,
LMTK2 levels were reduced in cortex in both Braak
stage III-IV and stage VI cases. By contrast, in cerebel-
lum LMTK2 levels were unaffected in Braak stage III-IV
but were elevated in Braak stage VI cases (Fig. 7). These
data suggest that loss of LMTK2 in dementia may con-
tribute to neuronal dysfunction by disruption of axonal
transport of key cargoes through axons.
Discussion
Here we show that LMTK2 binds to kinesin-1 light
chains and that this involves interactions between the
KLC TPR domains and a C-terminal WD motif
(WD1388/1389) in LMTK2. We also demonstrate that
binding of LMTK2 to KLCs facilitates its transport into
and through axons of neurons. Thus, mutation of
LMTK2(WD1388/1389) to inhibit binding to KLCs and
siRNA loss of KLC1 both reduce axonal LMTK2 levels
and anterograde axonal transport of LMTK2 in living
neurons.
LMTK2 also binds to the cdk5 activator protein p35
[18]. cdk5/p35 is a key neuronal kinase that regulates a
number of fundamental cellular functions in both axons
and synapses but the mechanisms by which it is trans-
ported to these locations are unknown [20, 43]. We
show that LMTK2 mediates the formation of a
KLC1-LMTK2-p35 complex and that siRNA loss of
LMTK2 perturbs axonal transport and axonal delivery
of p35. We also show that siRNA loss of LMTK2
disrupts axonal transport of cdk5. Together, these find-
ings demonstrate that LMTK2 is required for proper
axonal delivery and anterograde axonal transport of
both p35 and cdk5.
siRNA knockdown of KLC1 and mutation of
LMTK2(WD1388/1389) both reduced but did not elim-
inate axonal LMTK2 levels and anterograde axonal
transport of LMTK2. The remaining transport of
LMTK2 in the KLC1 siRNA knockdown neurons may
be due to incomplete siRNA loss of KLC1 or the pres-
ence of KLC2 which we show also binds to LMTK2.
Likewise, the remaining anterograde movement of mu-
tant LMTK2(WD1388/1389AA) may be due to move-
ment on KLC2 containing motors since we show that
the LMTK2 WD mutations abrogate binding to KLC1
but only reduce binding to KLC2. Others have described
differences in binding of WD/WE containing cargo pro-
teins to KLC1 and KLC2 [10, 49].
In a similar fashion, knockdown of LMTK2 did not
completely block transport of p35 and cdk5. This could
again be a consequence of incomplete siRNA loss of
LMTK2. Interestingly however, a further member of the
LMTK family, LMTK1 (also known as AATYK1) has
also been shown to bind to p35 so it is possible that
LMTK1 acts to scaffold p35 to KLCs in a manner simi-
lar to that of LMTK2 [48]. Indeed, like LMTK2, LMTK1
contains a conserved C-terminal WD motif. Thus, at
least two members of the LMTK family may function as
scaffolding ligands for KLCs.
Damage to p35 and disruption of cdk5/p35 activity
are strongly linked to Alzheimer’s disease [7, 41, 43].
Moreover, abnormal cell body accumulation of cdk5/
p35 is observed in affected regions in post-mortem
Alzheimer’s disease brains [25, 38, 39, 57]. Such accu-
mulations are consistent with disruption to axonal
transport of cdk5/p35. Damage to axonal transport is
a major feature of Alzheimer’s disease [2, 5, 9, 30, 55].
Of interest therefore were our findings that LMTK2
levels are reduced in Alzheimer’s disease cortex (af-
fected region) and that this reduction occurs in mid
(Braak stage III-IV) as well as severe (Braak stage VI)
dementia cases. This loss of LMTK2 in Braak stage
III-IV cortex suggests that it is may be an early patho-
genic feature; early pathogenic events are generally
believed to contribute most to the disease process. In
contrast to the Alzheimer’s disease cortex, LMTK2
levels were elevated in Braak stage VI cerebellum.
Whether this increase in cerebellar LMTK2 levels
contributes to any protection from the neurodegenera-
tive process in this brain region is not clear. Since we
show that LMTK2 mediates axonal transport of p35
and cdk5, this loss of LMTK2 may contribute to the
cell body cdk5/p35 accumulation that has been
described in Alzheimer’s disease [25, 38, 39, 57].
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Aside from binding to KLCs and p35, LMTK2 also in-
teracts with the molecular motor protein myosin VI and
the catalytic subunit of protein phosphatase-1 (PP1C)
[8, 16, 27, 53]. These interactions involve domains
within LMTK2 that are distinct from the KLC WD inter-
action motif that we identify here. The LMTK2-myosin VI
interaction regulates endosome trafficking and delivery of
proteins to axonal membranes [8, 16, 24]. The interactions
between cdk5/p35, LMTK2 and PP1 have been shown to
form a signaling pathway that regulates the activity of
glycogen synthase kinase-3β (GSK-3β) [27, 28, 32].
Like cdk5/p35, PP1C and GSK-3β are key signaling
molecules within neurons [15, 35]. In this pathway,
cdk5/p35 phosphorylates and activates LMTK2 which
in turn induces inhibitory phosphorylation of PP1C
on threonine-320; this leads to increased inhibitory
phosphorylation of GSK-3β on serine-9. One target of
this signaling involves GSK-3β phosphorylation of
KLC2 which causes release of some cargoes to inhibit
their transport [27, 32].
Thus, LMTK2 is centrally placed to regulate a number
of fundamental transport processes within axons includ-
ing those driven by kinesin-1 and myosin VI. This regu-
lation may be via scaffolding functions that deliver
LMTK2 and interacting partners such as p35 and cdk5
to axons as we describe here, and also signaling func-
tions involving cdk5/p35, PP1C and GSK-3β activities.
Moreover, like cdk5/p35, both PP1 and GSK-3β are
strongly linked to the pathogenesis of Alzheimer’s dis-
ease [6, 14, 22, 26]. The loss of LMTK2 that we de-
scribe in Alzheimer’s disease brains may therefore
impact on both axonal transport and neuronal signal-
ing functions which are all perturbed in dementia.
Our discovery that LMTK2 is a KLC binding protein
that facilitates axonal transport of cdk5/p35 provide
the basis for a proper dissection of such functions.
They also pave the way for further studies of LMTK2
in Alzheimer’s disease post-mortem tissues and in
transgenic mouse models of Alzheimer’s disease. In
this context it is noteworthy that as we show in the
post-mortem human tissues, LMTK2 levels are also
reduced in cortex and increased in cerebellum in
some transgenic mouse models of Alzheimer’s disease
[29]. Future studies could therefore include correlat-
ing levels of LMTK2 to those of phosphorylated Tau,
Table 1 Data for human post-mortem samples showing age at
death, sex, post-mortem delay and pathological diagnosis
Case Group Autopsy Code Sex Age Post-Mortem
Delay (hrs)
Braak stage
Control A002/13 M 90 45 –
Control A007/15 F 74 64 II
Control A033/11 M 82 47 I
Control A046/12 F 92 9 II
Control A048/09 M 82 18 –
Control A063/10 F 90 50 II
Control A082/14 M 68 60 II
Control A105/14 F 77 21 –
Control A158/14 F 73 27 I
Control A209/13 M 80 55 II-III
Control A213/12 M 78 24 III
Control A308/09 M 66 52 –
Control A319/14 F 90 44 II
Control A346/10 F 84 34 I-II
Control A407/13 F 80 22 II
AD Braak III-IV A037/04 F 96 39 IV
AD Braak III-IV A041/04 F 97 67.5 III-IV
AD Braak III-IV A065/16 M 91 48 IV
A DBraak III-IV A067/09 F 92 19.5 III
AD Braak III-IV A078/13 M 86 52.5 IV
AD Braak III-IV A084/16 F 86 55.5 IV
AD Braak III-IV A097/13 M 82 28 IV
AD Braak III-IV A101/08 F 92 29.5 IV
AD Braak III-IV A189/07 F 83 41.5 IV
AD Braak III-IV A223/12 F 83 22 IV
AD Braak III-IV A232/16 F 95 47 IV
AD Braak III-IV A282/11 M 93 13.5 IV
AD Braak III-IV A374/14 M 88 79 III-IV
AD Braak III-IV A378/14 M 98 53 IV
AD Braak III-IV A381/16 M 84 86 IV
AD Braak VI A008/12 M 66 41 VI
AD Braak VI A064/16 F 93 49 VI
AD Braak VI A087/16 F 89 38.5 VI
AD Braak VI A100/15 F 73 30 VI
AD Braak VI A105/13 F 81 17.5 VI
AD Braak VI A166/12 F 86 25 VI
AD Braak VI A171/14 M 84 67 VI
AD Braak VI A226/16 F 69 73 VI
AD Braak VI A258/16 M 67 39.5 VI
AD Braak VI A289/13 M 83 22 VI
AD Braak VI A331/15 M 86 38 VI
AD Braak VI A342/14 F 84 27 VI
AD Braak VI A355/14 F 79 31 VI
Table 1 Data for human post-mortem samples showing age at
death, sex, post-mortem delay and pathological diagnosis
(Continued)
Case Group Autopsy Code Sex Age Post-Mortem
Delay (hrs)
Braak stage
AD Braak VI A377/14 F 85 79 VI
AD Braak VI A380/13 F 81 20 VI
AD Alzheimer’s disease, F female, M male
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Aβ, cdk5, p35 and GSK3β, and complementary im-
munohistochemical studies of LMTK2, Tau, cdk5
and p35.
Conclusions
LMTK2 is a neuronal serine/threonine kinase that binds
to the cdk5 activator subunit p35. Here we show that
LMTK2 also binds to KLC1/2 and this facilitates its
transport into and through axons. The interaction in-
volves the TPR domains in KLC1/2 and a WD motif in
the C-terminus of LMTK2. We also show that LMTK2
facilitates the formation of a complex containing KLC1
and p35 and that siRNA loss of LMTK2 disrupts axonal
transport of both p35 and cdk5. Finally, we show that
LMTK2 levels are reduced in affected cortical regions in
post-mortem Alzheimer’s disease brains. Defective cdk5/
p35 activity and damage to axonal transport are both
features of Alzheimer’s disease. Thus, LMTK2 binds to
KLC1 to direct axonal transport of p35 and its loss may
contribute to Alzheimer’s disease.
Additional file
Additional file 1: Figure S1. siRNA knockdown of KLC1 and LMTK2 in
rat cortical neurons. Knockdown of KLC1 does not affect expression of
LMTK2, kinesin-1, KLC1, p35, cdk5 or tubulin. siRNA knockdown of LMTK2
in rat cortical neurons does not affect expression of kinesin-1, KLC1, p35,
cdk5 or tubulin. siRNAs for LMTK2 and KLC1 have been described previously
[27, 51]. Figure S2. Characterisation of KLC1-p35 PLAs in rat primary
neurons. PLAs were performed with no primary antibodies, goat anti-KLC1
antibody alone, rabbit anti-p35 antibody alone or both KLC1 and p35
antibodies. Scale bar = 20 μm. Graph shows quantification of PLA signals in
the different treated neurons. Neurons we also immunostained for tubulin
to reveal neuronal architecture. Arrows show KLC1-p35 signals in axons.
Data were analysed by Welch’s ANOVA and Games-Howell post hoc test;
N = 25, ***p < 0.001. (DOCX 225 kb)
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Fig. 7 LMTK2 levels are reduced in post mortem Alzheimer’s disease cortex but not cerebellum. Representative immunoblots showing LMTK2
and NSE levels in post mortem human control (Ctrl) and Alzheimer’s disease cortex and cerebellum. Graphs show quantification of LMTK2 levels
in the different samples normalised to NSE levels. Data were analysed by one-way ANOVA and Holm-Sidak post hoc test, error bars are s.e.m.,
*p < 0.05 **p < 0.01, ns not significant
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